

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHS Scotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within a particular health board because of available services and preferences for alternative medicines.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The ADTC, Grampian Area Drug and Therapeutics Committee, is responsible for advising NHS Grampian health board on all aspects of the use of medicines.

Medicines routinely available within NHS Grampian are usually included in the Grampian Joint Formulary. The formulary is a list of medicines for use in the health board that has been agreed by the ADTC in consultation with local clinical experts. It offers a choice of medicines for healthcare professionals to prescribe for common medical conditions. A formulary can help improve safety as prescribers are likely to become more familiar with the medicines in it and also helps make sure that standards of care are consistent across the health board.

### How does the health board decide which new medicines to make routinely available for patients?

The ADTC in a health board will consider national and local guidance before deciding whether to make a new medicine routinely available.

### What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland, it looks at:
  - how well the medicine works,
  - which patients might benefit from it,
  - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
  - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence Multiple Technology Appraisals (NICE MTAs) are applicable in Scotland.

### What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in a health board.

### Why is a particular medicine not routinely available in NHS Grampian?

- This is usually because the medicine is not recommended for use in NHS Scotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences as to which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board consider whether to add new medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

### What happens if a particular medicine is not routinely available in NHS Grampian?

- If a medicine is not routinely available and not included in the Grampian Joint Formulary and there are no suitable alternatives on the formulary, a healthcare professional can request to prescribe a medicine that is not on the formulary if they think you will benefit from using it. All health boards have procedures in place to consider requests when a healthcare professional feels a medicine that is not on the formulary would be right for a particular patient.

The table below lists NHS Grampian's latest decisions on medicines.

If you need more information on medicines decisions in NHS Grampian, please email [gram.formularyteam@nhs.scot](mailto:gram.formularyteam@nhs.scot).

Image courtesy of Baitong333 - image ID: 100128772/ [FreeDigitalPhotos.net](https://www.FreeDigitalPhotos.net)

This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245.

NHS Grampian New Medicines Decisions – Formulary Group decisions 19 April 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
bambuterol 10mg tablets (Bambec®)		Management of asthma, bronchospasm and/or reversible airways obstruction.	This medicine is now withdrawn from use/discontinued	19/04/2022
belimumab 120mg, 400mg powder for concentrate for solution for infusion, 200mg solution for injection in pre-filled pen (Benlysta®)	<a href="#">2483</a>	In combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.	Not routinely available as not recommended for use in NHS Scotland, SMC 2483 <a href="https://www.scottishmedicines.org.uk/media/6791/belimumab-benlysta-non-sub-final-march-2022-for-website.pdf">https://www.scottishmedicines.org.uk/media/6791/belimumab-benlysta-non-sub-final-march-2022-for-website.pdf</a>	19/04/2022
berotralstat 150mg hard capsules (Orladeyo®)	<a href="#">2405</a>	Routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescent aged 12 years and older who experience two or more clinically significant attacks per month.	Routinely available in line with national guidance, SMC 2405 <a href="https://www.scottishmedicines.org.uk/media/6734/berotralstat-orladeyo-final-feb-2022-amended-220222-for-website.pdf">https://www.scottishmedicines.org.uk/media/6734/berotralstat-orladeyo-final-feb-2022-amended-220222-for-website.pdf</a>	19/04/2022
budesonide 9mg prolonged release tablet (Cortiment®)	<a href="#">2448</a>	Induction of remission in patients with active microscopic colitis.	Routinely available in line with national guidance, SMC 2448 <a href="https://www.scottishmedicines.org.uk/media/6584/budesonide-cortiment-abbreviated-final-dec-2021.docx-for-website.pdf">https://www.scottishmedicines.org.uk/media/6584/budesonide-cortiment-abbreviated-final-dec-2021.docx-for-website.pdf</a>	19/04/2022
carfilzomib 10mg, 30mg, 60mg powder for solution for infusion (Kyprolis®)	<a href="#">2484</a>	In combination with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2484 <a href="https://www.scottishmedicines.org.uk/media/6792/carfilzomib-kyprolis-non-sub-final-march-2022-for-website.pdf">https://www.scottishmedicines.org.uk/media/6792/carfilzomib-kyprolis-non-sub-final-march-2022-for-website.pdf</a>	19/04/2022

NHS Grampian New Medicines Decisions – Formulary Group decisions 19 April 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
chlorpromazine 50mg/2mL solution for injection ampoules (Largactil®)		Indicated in the following conditions: - Schizophrenia and other psychoses (especially paranoid) mania and hypomania - Anxiety, psychomotor agitation, excitement, violent or dangerously impulsive behaviour. Largactil is used as an adjunct in the short-term treatment of these conditions - Intractable hiccup - Nausea and vomiting of terminal illness (where other drugs have failed or are not available) - Childhood schizophrenia and autism	This medicine is now withdrawn from use/discontinued	19/04/2022
fedratinib 100mg hard capsules (Inrebic®)	<a href="#">2462</a>	For the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/04/2022
ibrutinib 140mg, 280mg, 420mg, 560mg film coated tablets (Imbruvica®)	<a href="#">2485</a>	In combination with rituximab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.	Not routinely available as not recommended for use in NHS Scotland, SMC 2485 <a href="https://www.scottishmedicines.org.uk/media/6794/ibrutinib-imbruvica-non-sub-march-2022-for-website.pdf">https://www.scottishmedicines.org.uk/media/6794/ibrutinib-imbruvica-non-sub-march-2022-for-website.pdf</a>	19/04/2022

NHS Grampian New Medicines Decisions – Formulary Group decisions 19 April 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
micronised progesterone 400mg pessaries (Cyclogest®)	446/22	[Off-label use] Management of threatened miscarriage in women with vaginal bleeding who have a confirmed pregnancy and with a history of one or more previous miscarriages. <b>Restriction:</b> in line with local guideline 'Management of threatened miscarriage (including the use of progesterone where applicable)'	Routinely available in line with local guidance	19/04/2022
micronised progesterone 200mg pessaries (Cyclogest®)	446/22	[Off-label use] Management of threatened miscarriage in women with vaginal bleeding who have a confirmed pregnancy and with a history of one or more previous miscarriages. Restriction: in line with local guideline 'Management of threatened miscarriage (including the use of progesterone where applicable)'	Decision deferred to future meeting	19/04/2022
micronised progesterone 200mg vaginal capsules (Utrogestan Vaginal®)	447/22	[Off-label use] Management of threatened miscarriage in women with vaginal bleeding who have a confirmed pregnancy and with a history of one or more previous miscarriages. <b>Restriction:</b> in line with local guideline 'Management of threatened miscarriage (including the use of progesterone where applicable)'	Decision deferred to future meeting	19/04/2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
risankizumab 150mg solution for injection in a prefilled syringe, pen (Skyrizi®)	<a href="#">2459</a>	<p>Alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).</p> <p><b>SMC restriction:</b> (i) patients whose disease has not responded adequately or who have been intolerant to two previous conventional disease-modifying antirheumatic drug (DMARD) therapies but have not received biologic DMARD therapy (biologic-naïve population); (ii) patients whose disease has not responded adequately to conventional DMARDs and one or more tumour necrosis factor (TNF) inhibitors (biologic-experienced population); and (iii) patients in whom TNF inhibitors are contraindicated or not tolerated.</p>	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/04/2022
risankizumab 150mg solution for injection in a prefilled syringe, pen (Skyrizi®)		<p>For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.</p> <p><b>Restriction:</b> for patients who have failed to respond to conventional systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contraindication to these treatments.</p>	Routinely available in line with national guidance, SMC 2196	19/04/2022

NHS Grampian New Medicines Decisions – Formulary Group decisions 19 April 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
risankizumab 75mg solution for injection in pre-filled syringe (Skyrizi®)		<p>Indications:</p> <ul style="list-style-type: none"> <li>- for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.</li> <li>- alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).</li> </ul>	This medicine is now withdrawn from use/discontinued	19/04/2022
tipranavir 250mg soft capsule, 100mg/mL oral solution (Aptivus®)		For the treatment of HIV-1 infection in highly pre-treated patients aged 2 years and older with virus resistant to multiple protease inhibitors.	This medicine is now withdrawn from use/discontinued	19/04/2022
Triapin® 5mg/5mg modified-release tablets (felodipine/ramipril)		For the treatment of hypertension.	This medicine is now withdrawn from use/discontinued	19/04/2022
upadacitinib 15mg, 30mg prolonged-release tablets (Rinvoq®)	<a href="#">2417</a>	<p>For the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.</p> <p><b>SMC restriction:</b> patients who have had an inadequate response to at least one conventional systemic immunosuppressant such as ciclosporin, or in whom such treatment is considered unsuitable.</p>	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/04/2022
venetoclax 10mg, 50mg, 100mg film-coated tablets (Venclyxto®)	<a href="#">2412</a>	In combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/04/2022